Wednesday 9 July 2014

Novel Antibody Obliterates Psoriasis (CME/CE)

(MedPage Today) -- Treatment of longstanding moderate-to-severe plaque psoriasis with secukinumab was associated with rapid and dramatic improvements, two large phase III clinical trials found. via MedPageToday.com - medical news plus CME for physicians Read More Here..

No comments:

Post a Comment